Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine during liver cancer resection and postoperative recurrence/metastasis
ChiCTR1900022415Phase 4Recruiting
- Sponsor
- Department of Anesthesiology and Perioperative Medicine, Second Hospital of Anhui Medical University
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Department of Anesthesiology and Perioperative Medicine, Second Hospital of Anhui Medical University. Primary endpoints: Long-term survival rate, Tumor recurrence in situ and distant metastasis and 2 more. Started Apr 2019; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900022415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022415.